Outlook Therapeutics
OTLK
17 hedge funds and large institutions have $4.96M invested in Outlook Therapeutics in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
0% more funds holding
Funds holding: 17 → 17 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
3.06% less ownership
Funds ownership: 18.51% → 15.45% (-3.1%)
87% less capital inflows, than outflows
Capital inflows: $147K | Capital outflows: $1.13M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$40.8K |
| 2 |
Two Sigma Securities
New York
|
+$35.9K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$31.9K |
| 4 |
Panagora Asset Management
Boston,
Massachusetts
|
+$30.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cormorant Asset Management
Boston,
Massachusetts
|
-$730K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$395K |
| 3 |
Virtu Financial
New York
|
-$1.04K |
OTLK Hedge Fund Activity: Q4 2017 in Review
17 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q4 2017, worth a combined $4.96M — down 20% from $6.16M a quarter earlier.
Fund positioning in OTLK was balanced in Q4 2017: 1 fund opened new positions, 1 closed out, 6 added to existing stakes and 3 trimmed.
The largest buyer was Bank of America, adding an estimated $40.8K. The largest seller was Cormorant Asset Management, cutting an estimated $730K.
- 17 institutional investors held Outlook Therapeutics (OTLK) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $4.96M of Outlook Therapeutics stock for Q4 2017, down 20% quarter-over-quarter.
- 1 fund opened new Outlook Therapeutics positions in Q4 2017 and 1 closed out, a net change of 0 holders.
- The largest Outlook Therapeutics buyer in Q4 2017 was Bank of America, an estimated $40.8K added.
- The largest Outlook Therapeutics seller in Q4 2017 was Cormorant Asset Management, an estimated $730K sold.
Based on aggregated 13F filings for Q4 2017.